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Effects of Synthetic Colloids
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Ideal Colloid
 Less coagulopathy, hemolysis, red cell hemolysis, 
cross-match disturbances
 Rapid volume replacement
 Good hemodynamic restoration
 Improvement of Microcirculation
 Improvement of plasma oncotic pressure
 Increase DO2 and organ function
 Fast metabolism / excretion and good tolerance
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DISADVANTAGE EFFECTS OF SYNTHETIC 
COLLOID
 Coagulation dilution: (decrease vWF; platelet 
adhesion ↓) Dextran , HMW. HES & high dose/ 
multiple
 Renal function: Dextran, HMW. HES and high DS 
(450 kD/ 0.7)
 Tissue Accumulation: HMW. HES / high DS 
( RES, skin , nerve )
HES = Hydroxethylstarch
(Not all HES are the same!)
Tetrastarch (0.4) Pentastarch (0.5) Hetastarch (0.7)
HES 130 /0.4                                          HES 200 /0.5                                      HES 450 /0.7
(Based on degree of substitution)
(Based on Molecular weight)
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HES 470 /0.7
HES 200 /0.5
HES 200 /0.62
HES 40 /0.5
HES 70 /0,5
HES 110 /0,5
HES 130 /0,4Hespan
Plasmasteril
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Effects of PVR solutions 
on haemostasis and coagulation
Gelatins HMW. HES Dextrans 
Factor VIII, vWF No effect
Platelets
 Adhesion
 Aggregation
No effect
Thrombus formation No clinical effect
Blood typing No effect In emergency 
situation blood typing 
prior to infusion !
Tetrahes structure
 HES  similar to glycogen  consists of: 
 D- glucose units linked via linear alpha – 1,4 
bonds  and branching off from about one in every 
17 glucose units via  alpha-1.6 bonds
 Hydroxyethyl groups  more resistant to 
enzymatic degradation and the longer its 
intravascular residence time 
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Schematic Representation 
of HES molecule
Characteristic of 6% HES 130/0.4
 6% HES 130/0.4 in 0.9% sodium chloride sol.
 Mean Molecular Weight      130.000 ±20.000 Da
 Molecular DS                            0.38- 0.45
 C2 / C6 substitution pattern        ≥ 8
 Sealing effect                            positive
 Water binding capacity           21ml H2O/g HES
 Colloid Osmotic Pressure            36 mmHg
 Theoritical osmolarity 308  mosm/l
 pH value                                  4.0-5.5
 Titration acidity                        < 1.0 mmol/l NaOH
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Extent and Duration of Volume
expansion ( Tetrahes )
 Concentration  :  6%
 Degree of mollar substitution ( MS ): 0.4 
 4 hydroxyethyl group per 10 glucose unit 
 Sustitution pattern ( site of hydroxyethylation ) 
position 2,3, and 6 of the glucose unit. Ratio C2/C6 > 8
Structural formula of HES and mode of steric 
interference with degradation by amylase
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HES 130/0.4 ( TETRAHES )
 HES 130/0.4  130.000 MW, DS 0.4 and improved 
C2/C6 ratio ( > 8 )
 Advantages
No tissue storage; Quickly excreted; 
Improve safety profil (hemostasis ); 
Comparable macro/microcirculatory efficacy
Initial volume efficacy 
Good hemorrheology
Complete elimination
Maximal Dose : 50 ml/kg/day 
Pharmacodynamic Studies
On Volume Effect
 12 Volunteers: 500 ml blood letting 30 ’; single 
inf.500 ml HES 130/0.4 15 ’. Results: Reduction 
in Ht, Increase in plasma volume/ blood 
volume; Volume effect 100%; Plateau effect 4 
hours; Volume effect 6 hours
RCT of HES 130/0.4 in variety of clinical 
situation  HES 130/0.4 is a comparable in 
efficacy to HES 200/0.5 (Kapser, Boldt, 
Langeron, Huet, Vogt)
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Volume Therapy
With HES 130/0.4
 The extent & Duration of the Volume Effect 
Vital for macro & microcirculation
A fast & effective replacement of the 
intravascular volume  optimize capillary 
perfusion; improve blood rheology & its O
2
transport capacity  prevent excessive release 
of mediators & MOF (Bold, 1998) 
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Influence On Macro and Microcirculation
 Effective volume replacement  improved 
acute and chronic macro & microcirculation 
disturbances
 ↑ perfusion pressure and ↓ blood / plasma 
viscosity improve rheological properties 
improvement in the microcirculation 
Stimulation of
Pro-inflammatory Process
No cytokines release in vitro 
No affecting on various surface antigens
No affecting on adhesion molecules on 
monocytes and endothelial cells
(Dietrich et al 1998)
• Slightly reduce plasma concentration of 
adhesion molecules (Boldt et al, 1998)
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Problems in Colloid Therapy
 “We are just giving colloid to the patient!
 What should happen?”
Possible side effects amongst others can be:
 Influence on Renal Function
 Influence on coagulation
 Anaphylaxis reaction
 Tissue accumulation
 Acid base balance disturbances
Safety Profile
Of HES 130/0.4
 Influenced on Hemostasis
Fast & complete elimination  minimal 
influence on coagulation
Evidence showed that after HES 130/0.4 
faster recovery of the vWF and Ristocetin co-
factor compared to HES 200/0.5 (Vogt et al 
1998, Bepperling et al 1999, Jungheinrich C et 
al 2004) 
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Anaphylactoid Reactions
 The lowest rate of allergic reaction of all 
colloids (0.06%)
Major anaphylactoid reaction (gr III & IV) are 
seldom during HES therapy (Ring and Mezmer, 
1997 ; Laxenaire et al, 1994)
No Influenced on 
The Normal Kidney
No affect on the healthy kidney, if the dosage 
instructions are not exceeded
After long-term HES therapy could be caused 
by reduced diuresis as a result of hyperviscosity
of renal tubular
 Evidenced showed: HES 130/0.4 safely 
administered to patients with severe renal 
impairment as long as urine flow is preserved 
(Jungheinrich, et al 2002)
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Relevance of Mol Weight, Molar Substitution and 
C
2
:C
6
- ratio
 Influence on Kidney function and coagulation 
depend on MS,C2:C6 than MW  
MS >> C2: C6 > MW
MW/MS/C2:C6
200/0.5/ 5:1
130/0.4/9:1
130/0.42/6:1
TETRAHES
( 6% HES 
130/0.4)
GOOD INTRAVASCULAR VOLUME EFFECT
IMPROVEMENT OF MACRO & MICROCIRCULATION
MINIMAL SIDE EFFECT  (COAGULATION, RENAL,
ANAPHYLACTOID RX, TISSUE ACCUMULATION)
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